Core Viewpoint - Rocket Pharmaceuticals is facing a class action lawsuit due to allegations of misleading investors regarding the safety and protocol of its clinical trials for gene therapies [3][4]. Group 1: Company Overview - Rocket Pharmaceuticals is a late-stage biotechnology company focused on developing gene therapies for rare and serious diseases [2]. Group 2: Legal Allegations - The class action lawsuit claims that Rocket Pharmaceuticals provided updates on its Phase 2 trial of RP-A501 for Danon disease while making materially false statements and omitting critical adverse facts about the trial's safety [3]. - The lawsuit alleges that the company was aware of the risk of Serious Adverse Events (SAEs), including patient deaths, but did not fully inform investors [3]. - It is claimed that Rocket Pharmaceuticals amended the trial protocol to include a new immunomodulatory agent without disclosing this change to shareholders [3]. Group 3: Impact of FDA Action - On May 27, 2025, Rocket Pharmaceuticals announced that the U.S. FDA had placed a clinical hold on the RP-A501 Phase 2 trial following the death of a participant treated under the amended protocol, which had not been disclosed to investors [4]. - Following this announcement, Rocket Pharmaceuticals' stock price experienced a decline [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study following a Serious Adverse Event [3][4]. Summary by Relevant Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol, including the risk of Serious Adverse Events (SAEs) and participant deaths [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a patient's death linked to the trial, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [3]. Class Action Details - The class period for the lawsuit is from February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [4]. - Shareholders who register will receive updates on the case's progress through portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, seeking recovery for losses incurred due to misleading statements by companies [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the announcement of a clinical hold by the FDA [2][3]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths during the clinical trial [2]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [2]. - Following the FDA's announcement of a clinical hold on May 27, 2025, due to a SAE resulting in a participant's death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Class Action Details - The class period for the lawsuit is defined as February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [3]. - Shareholders who register will receive updates on the case's progress through portfolio monitoring software [3]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit ...

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price following the announcement of a clinical hold by the FDA [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths during the clinical trial [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. Stock Price Impact - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share, marking a decline of approximately 37% in just one trading day [3]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for August 11, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. Law Firm Background - The Gross Law Firm, which is leading the class action, is recognized for protecting investors' rights against deceit and fraud, aiming to recover losses incurred due to misleading statements by companies [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing allegations of providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant stock price decline after the FDA placed a clinical hold on the study due to serious adverse events, including a participant's death [1]. Summary by Relevant Sections Allegations - The complaint states that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol [1]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which misled investors into purchasing shares at inflated prices [1]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a serious adverse event, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [1]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action lawsuit, with a deadline of August 11, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions [3].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the safety and clinical trial protocol for its drug RP-A501, which is intended for the treatment of Danon disease [4][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey on behalf of investors who purchased Rocket securities between February 27, 2025, and May 26, 2025 [4]. - Allegations include that the defendants made false statements about the safety of RP-A501 and failed to disclose serious adverse events, including participant deaths during the clinical trial [5]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiffs must file their papers by August 11, 2025, with the understanding that participation as a lead plaintiff is not necessary to share in any potential recovery [6]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [6]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation, being recognized multiple times by The National Law Journal and The Legal 500 [7].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals provided misleading information regarding the safety and clinical trial protocol of RP-A501, particularly concerning serious adverse events, including participant deaths [3][4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a serious adverse event, which was not disclosed to investors prior to the protocol amendment [4]. Group 2: Lead Plaintiff Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and can select a law firm to litigate the lawsuit [5]. Group 3: Company Background - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare diseases [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading information about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided investors with misleading information regarding the Phase 2 pivotal trial of RP-A501 for Danon disease, while concealing serious risks, including the death of participants [3]. - It is alleged that the company amended the trial protocol to include a new immunomodulatory agent without disclosing this critical update to shareholders [3]. - Following the announcement of a clinical hold by the FDA due to a serious adverse event, including a participant's death, the stock price of Rocket Pharmaceuticals fell significantly [4]. Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6].